With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets.

Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports current and forecasted revenues for the implantable/injectable drug delivery market, segmented into two main categories:

• Needle-free drug delivery
• Other Injectable/Implantable

Kalorama's unique analysis offers segmentation of this market for:

• Drug Delivery Technology Revenues
• Pharmaceuticals Sold via Delivery Technology

This breakout makes the report relevant to business plans of either device technology companies or pharmaceutical concerns. (This market analysis does not include drug-eluding stents or prefilled or regular syringes. Kalorama considers these separate markets)

The report covers both pharmaceuticals sold through implantable/injectable delivery systems and the technologies themselves including:

• Detailed Profiles of Key Companies in Implantable/Injectable Delivery
• Brief Round-Up of Smaller Players
• Current Market Size and Forecasts to 2013
• Needle-Free Cost Savings, Protein-Coated Microcrystal Technology, Nanotechnology, and Other Trends and Developments
• Revenue Forecasts
• New Products in Development

Kalorama’s trusted information-gathering process provides most accurate study of the implantable/injectable delivery drug market available today. Information and analysis presented in this report is based on extensive interviews with senior management of top companies in the industry. While major research literature and government information is culled, information is corroborated and key market insights originate from interviews with industry leaders.

Companies Profiled in the report include:

• Alkermes, Inc.
• ALZA Corp.
• Antares Pharma, Inc.
• Bioject Medical Technologies, Inc.
• CyDex, Inc.
• MGI Pharma, Inc
• Nektar Therapeutics
• Pacira Pharmaceuticals, Inc.
• pSivida
• SurModics, Inc
• Zogenix Corporation
• AP Pharma
• Baxter BioPharma Solutions
• QLT USA, Inc
• Ypsomed Holding AG

Kalorama has also published Drug Delivery Markets: Oral Delivery, which details markets for oral technology enhancements which have increased drug product sales and extended patent life.

Related Reports:

What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline
Feb 1, 2010 - KLI2578515 - $4,200.00

Veterinary Diagnostics Markets
Oct 1, 2009 - KLI2430295 - $995.00

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Oct 1, 2009 - KLI2384194 - $3,995.00

The World Market for Biosimilars and the Potential for US Follow-on Biologics
Aug 1, 2009 - KLI2402283 - $3,700.00

Drug Delivery Markets: Oral Delivery
Jul 1, 2009 - KLI2290102 - $2,995.00

Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Jun 1, 2009 - KLI2155319 - $3,995.00

H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
May 1, 2009 - KLI2241990 - $800.00

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
May 1, 2009 - KLI2218043 - $3,995.00

World Veterinary Health Products (Animal Pharmaceuticals, Vaccines, OTC and Performance Enhancers)
May 1, 2009 - KLI1829596 - $3,500.00

Cell Culture: The World Market for Media, Sera and Reagents, 2nd Edition
May 1, 2009 - KLI2091313 - $3,995.00